XPH: Revenue Challenges Ahead For U.S. Pharmaceuticals (Archive)
XPH faces looming patent cliffs and riskier orphan drug bets, pressuring future alpha.
This 5-Minute Pitch was originally published on Seeking Alpha before the launch of the Hunting Alphas website. It is shared here to showcase my previous work and track record. New 5-Minute Pitches published on this site will not be disseminated anywhere else.
Elevator Pitch
- XPH gives you exposure to a broad-based cut of the US Pharmaceuticals sector.
- Patent expirations are a major headwind affecting many companies in the industry.
- Focus on orphan drug development leads to riskier revenue streams.
- Overall, XPH is unlikely to generate alpha over the S&P 500.
Read the full article here.
Disclosures and Disclaimers
Past performance ≠ future results. Not investment advice. See full Disclaimer.
Comments ()